Launch of TerugBetaalRegeling Broxil®
The health insurer does not fully reimburse Broxil® 125 mg / 5 mL, powder for oral suspension. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal Contribution to the patient.
The Personal Contribution for Broxil® 125 mg / 5 mL, powder for oral suspension that is demonstrably charged to the patient by the health insurer will be fully reimbursed from 1 Augustus 2020 up to a maximum of € 250 per patient per year. The arrangement is limited to patients who are dependent on this drug for (functional) asplenia or recurrent erysipelas. To be eligible, a Doctor's statement completed by the specialist is required.
Who can submit a claim
Only patients or their carer can submit a claim for the Personal Contribution paid for Broxil® 125 mg / 5 mL, powder for oral suspension online or by post. Online will be the fastest option. Pharmacists cannot submit claims for this medicine on behalf of the patient.